Cargando…
Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Despite the recent advances in controlling some viral pathogens, most viral infections still lack specific treatment. Indeed, the need for effective therapeutic strategies to combat ‘old’, emergent, and re-emergent viruses is not paralleled by the approval of new antivirals. In the past years, drug...
Autores principales: | Mercorelli, Beatrice, Palù, Giorgio, Loregian, Arianna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126639/ https://www.ncbi.nlm.nih.gov/pubmed/29759926 http://dx.doi.org/10.1016/j.tim.2018.04.004 |
Ejemplares similares
-
Drug Repurposing Campaigns for Human Cytomegalovirus Identify a Natural Compound Targeting the Immediate-Early 2 (IE2) Protein: A Comment on “The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts”
por: Mercorelli, Beatrice, et al.
Publicado: (2019) -
Early inhibitors of human cytomegalovirus: State-of-art and therapeutic perspectives
por: Mercorelli, Beatrice, et al.
Publicado: (2011) -
Divide et impera: An In Silico Screening Targeting HCMV ppUL44 Processivity Factor Homodimerization Identifies Small Molecules Inhibiting Viral Replication
por: Ghassabian, Hanieh, et al.
Publicado: (2021) -
Binding parameters and thermodynamics of the interaction of the human cytomegalovirus DNA polymerase accessory protein, UL44, with DNA: implications for the processivity mechanism
por: Loregian, Arianna, et al.
Publicado: (2007) -
A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells
por: Messa, Lorenzo, et al.
Publicado: (2018)